A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the recommended Phase II dose for the
combination of ABT-510 plus bevacizumab in patients with advanced solid tumors and to
evaluate dose limiting toxicities and non-dose limiting toxicities of this combination. The
secondary objectives are to collect preliminary data on the effect of the combination of
ABT-510 plus bevacizumab versus each agent individually on dermal wound angiogenesis in a
skin biopsy and to collect preliminary data on the clinical activity of this combination
(tumor response rate, progression-free survival, rate of stable disease > 6 months).